Sanofi steps up with its data on a new MS drug, shining a spotlight on PhIII hopes after fending off a short attack
Sanofi CEO Paul Hudson was drawn early on in his new job to a multiple sclerosis drug in the pipeline, talking it up ahead of the mid-stage data and later reserving a prominent place in the late-stage pipeline on the top-line readout. Sanofi has started to map out an ambitious Phase III effort aimed at taking it over the commercial line — even as they face delays inflicted by Covid-19.
On Thursday morning, researchers spelled out the data for the Phase IIb that give them confidence that SAR442168 has the potential to play a disruptive role in the MS market — where some tough competitors are roiling the field even as physicians and patients continue to press for more choices.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.